propylthiouracil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
uracil derivatives used as thyroid antagonists 2308 51-52-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • propylthiouracil
  • 6-n-Propylthiouracil
  • procasil
  • propacil
  • prothiurone
A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)
  • Molecular weight: 170.23
  • Formula: C7H10N2OS
  • CLOGP: 0.97
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 41.13
  • ALOGS: -2.56
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 75.53 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 85 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.34 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.18 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 28, 1947 FDA DAVA PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anti-neutrophil cytoplasmic antibody positive vasculitis 269.45 30.07 51 2064 2848 63484059
Antineutrophil cytoplasmic antibody positive 152.24 30.07 25 2090 605 63486302
Thyrotoxic crisis 117.29 30.07 21 2094 855 63486052
Hyperthyroidism 106.75 30.07 33 2082 14640 63472267
Vasculitis 99.74 30.07 33 2082 18176 63468731
Exposure during pregnancy 97.84 30.07 62 2053 155485 63331422
Liver transplant 75.05 30.07 17 2098 2274 63484633
Foetal exposure during pregnancy 68.08 30.07 29 2086 31933 63454974
Agranulocytosis 67.78 30.07 27 2088 25107 63461800
Acute hepatic failure 50.48 30.07 20 2095 18307 63468600
Pulmonary renal syndrome 42.20 30.07 8 2107 446 63486461
Pulmonary alveolar haemorrhage 36.03 30.07 11 2104 4657 63482250
Haemoptysis 35.85 30.07 18 2097 28708 63458199
Goitre congenital 34.00 30.07 4 2111 5 63486902
Congenital hypothyroidism 33.94 30.07 6 2109 226 63486681
Hypothyroidism 31.77 30.07 19 2096 42613 63444294
Maternal drugs affecting foetus 30.67 30.07 10 2105 5232 63481675
Cardiac arrest 30.52 30.07 25 2090 92520 63394387

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperthyroidism 67.49 42.56 18 511 10548 34945854
Foetal exposure during pregnancy 66.59 42.56 24 505 38077 34918325
Obstructive pancreatitis 53.12 42.56 9 520 595 34955807

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anti-neutrophil cytoplasmic antibody positive vasculitis 293.03 28.65 56 2329 3673 79738330
Antineutrophil cytoplasmic antibody positive 149.73 28.65 27 2358 1279 79740724
Thyrotoxic crisis 137.13 28.65 25 2360 1259 79740744
Hyperthyroidism 133.19 28.65 42 2343 22167 79719836
Vasculitis 96.63 28.65 34 2351 25068 79716935
Exposure during pregnancy 93.75 28.65 50 2335 101082 79640921
Agranulocytosis 70.92 28.65 32 2353 44998 79697005
Acute hepatic failure 59.11 28.65 25 2360 30088 79711915
Liver transplant 56.14 28.65 15 2370 4408 79737595
Cardiogenic shock 51.19 28.65 25 2360 41889 79700114
Obstructive pancreatitis 43.45 28.65 9 2376 881 79741122
Cardiac arrest 43.34 28.65 38 2347 172058 79569945
Pulmonary renal syndrome 40.32 28.65 8 2377 632 79741371
Glomerulonephritis rapidly progressive 37.93 28.65 9 2376 1639 79740364
Product administered to patient of inappropriate age 31.17 28.65 10 2375 5543 79736460
Circulatory collapse 30.32 28.65 17 2368 37651 79704352

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H03BA02 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
THYROID THERAPY
ANTITHYROID PREPARATIONS
Thiouracils
MeSH PA D000963 Antimetabolites
MeSH PA D013956 Antithyroid Agents
MeSH PA D006727 Hormone Antagonists
MeSH PA D009676 Noxae
CHEBI has role CHEBI:22586 antioxidants
CHEBI has role CHEBI:35221 antimetabolite
CHEBI has role CHEBI:49020 hormone antagonists
CHEBI has role CHEBI:50671 antithyroid drugs
CHEBI has role CHEBI:50903 carcinogen
CHEBI has role CHEBI:61908 nitric oxide synthase inhibitors
CHEBI has role CHEBI:74529 antidotes to acetaminophen poisoning
FDA MoA N0000175917 Thyroid Hormone Synthesis Inhibitors
FDA EPC N0000175918 Thyroid Hormone Synthesis Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Thyrotoxic crisis indication 29028009 DOID:12837
Hyperthyroidism indication 34486009 DOID:7998
Necrotizing vasculitis contraindication 11791001
Hyperbilirubinemia contraindication 14783006 DOID:2741
Agranulocytosis contraindication 17182001 DOID:12987
Hypothyroidism contraindication 40930008 DOID:1459
Interstitial pneumonia contraindication 64667001
Leukopenia contraindication 84828003 DOID:615
Pancytopenia contraindication 127034005 DOID:12450
Liver function tests abnormal contraindication 166603001
Drug-induced hepatitis contraindication 235876009
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Bone marrow depression contraindication 307762000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.52 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Thyroid peroxidase Enzyme INHIBITOR IC50 5.06 WOMBAT-PK CHEMBL
Type I iodothyronine deiodinase Enzyme INHIBITOR CHEMBL CHEMBL
Myeloperoxidase Enzyme IC50 5.55 CHEMBL
Taste receptor type 2 member 38 GPCR EC50 5.70 CHEMBL

External reference:

IDSource
4017432 VUID
N0000145820 NUI
D00562 KEGG_DRUG
4017432 VANDF
C0033511 UMLSCUI
CHEBI:8502 CHEBI
3CJ PDB_CHEM_ID
CHEMBL1518 ChEMBL_ID
DB00550 DRUGBANK_ID
D011441 MESH_DESCRIPTOR_UI
657298 PUBCHEM_CID
4184 INN_ID
6650 IUPHAR_LIGAND_ID
721M9407IY UNII
8794 RXNORM
2256 MMSL
5376 MMSL
d00361 MMSL
002137 NDDF
3814009 SNOMEDCT_US
387203007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Propylthiouracil HUMAN PRESCRIPTION DRUG LABEL 1 0228-2348 TABLET 50 mg ORAL ANDA 22 sections
Propylthiouracil Human Prescription Drug Label 1 33342-314 TABLET 50 mg ORAL ANDA 22 sections
Propylthiouracil HUMAN PRESCRIPTION DRUG LABEL 1 42254-010 TABLET 50 mg ORAL ANDA 18 sections
Propylthiouracil HUMAN PRESCRIPTION DRUG LABEL 1 67253-651 TABLET 50 mg ORAL NDA 23 sections
Propylthiouracil HUMAN PRESCRIPTION DRUG LABEL 1 68084-964 TABLET 50 mg ORAL NDA 24 sections
Propylthiouracil HUMAN PRESCRIPTION DRUG LABEL 1 68084-964 TABLET 50 mg ORAL NDA 24 sections
PROPYLTHIOURACIL HUMAN PRESCRIPTION DRUG LABEL 1 70752-171 TABLET 50 mg ORAL ANDA 21 sections
PROPYLTHIOURACIL HUMAN PRESCRIPTION DRUG LABEL 1 70752-171 TABLET 50 mg ORAL ANDA 21 sections
PROPYLTHIOURACIL HUMAN PRESCRIPTION DRUG LABEL 1 72162-2072 TABLET 50 mg ORAL ANDA 21 sections